| Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.Br J Cancer | PMID 35610366PMC9381581 | 2022-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.Ann Oncol | PMID 35636621无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.Br J Cancer | PMID 35637412PMC9427779 | 2022-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.Clin Lymphoma Myeloma Leuk | PMID 35643855无 PMCID | 2022-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.J Clin Psychopharmacol | PMID 35652746PMC9426730 | 2022 Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study.Clin Colorectal Cancer | PMID 35654691无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.J Thorac Oncol | PMID 35659580无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.Prostate | PMID 35675470无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.Support Care Cancer | PMID 35678882无 PMCID | 2022-Sep | 0.95 | The trial meets most criteria (oncology, human, randomized, Phase III, drug intervention, original result). However, the primary efficacy endpoint is 'proportion of patients achieving complete hematological response at 12 weeks', which is a categorical/binary outcome, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis involving Kaplan-Meier curves or hazard ratios. Therefore, it is excluded. | 待处理 |
| Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.Gastroenterology | PMID 35679950无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.Ann Oncol | PMID 35688358无 PMCID | 2022-Sep | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).Int J Clin Oncol | PMID 35723758无 PMCID | 2022-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).Cancer Sci | PMID 35754298PMC9459345 | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 35780807无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.Ann Intern Med | PMID 35785530PMC9258784 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.Eur Urol | PMID 35787935无 PMCID | 2022-Sep | 0.45 | The record is from a Phase III randomized controlled trial in human oncology, but the provided abstract is empty and no keywords or MeSH terms explicitly signal the presence of survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes. Without abstract content or other data confirming such outcomes, eligibility cannot be determined. | 待处理 |
| HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis.Radiother Oncol | PMID 35817323无 PMCID | 2022-Sep | 0.95 | The record is an interim safety and dosimetry report from a definitive Phase III RCT in oncology but lacks the required efficacy outcomes (e.g., survival, progression, recurrence) for KM digitization. Therefore, it is excluded. | 待处理 |
| Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?Mol Diagn Ther | PMID 35841457PMC9411088 | 2022-Sep | 0.90 | The record describes a viewpoint/commentary article analyzing the failure of a Phase III trial for mongersen in Crohn's disease (non-oncology). It is not an original report of a primary or secondary efficacy result from a randomized trial with a time-to-event endpoint (OS, PFS, etc.). | 待处理 |
| Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.Gynecol Oncol | PMID 35851489无 PMCID | 2022-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.Leukemia | PMID 35869266PMC9417985 | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.Ann Hematol | PMID 35869984PMC9375756 | 2022-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol | PMID 35908558无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol | PMID 35914542无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.Lancet Diabetes Endocrinol | PMID 35914543无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.Adv Ther | PMID 35917059PMC9402487 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.Lung Cancer | PMID 35917647无 PMCID | 2022-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.Clin J Am Soc Nephrol | PMID 35918106PMC9625096 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.Am J Clin Dermatol | PMID 35934770PMC9464749 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.Lancet Glob Health | PMID 35961356PMC9380257 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol | PMID 35963261无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 35964621无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.Nat Med | PMID 35995953PMC9499854 | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.JACC Heart Fail | PMID 36049817无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 36055304无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.Lancet Haematol | PMID 36055332无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever.Clin Exp Rheumatol | PMID 36106542无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.Clin Infect Dis | PMID 34940806PMC9427137 | 2022-Aug-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets.J Pediatr Endocrinol Metab | PMID 35700440无 PMCID | 2022-Aug-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.Vaccine | PMID 35933278无 PMCID | 2022-Aug-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.Orphanet J Rare Dis | PMID 36028858PMC9419398 | 2022-Aug-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.J Antimicrob Chemother | PMID 35762503无 PMCID | 2022-Aug-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.N Engl J Med | PMID 36001711无 PMCID | 2022-Aug-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.N Engl J Med | PMID 36001712无 PMCID | 2022-Aug-25 | 0.99 | The study is a Phase 3 randomized trial of a drug (olokizumab) in rheumatoid arthritis, which is not an oncology indication. The primary endpoint is an ACR20 response, a categorical/ordinal outcome at a fixed time point, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier or hazard ratio results are reported. | 待处理 |
| Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study.J Infect Dis | PMID 33351072PMC9400411 | 2022-Aug-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.Clin Infect Dis | PMID 34537835PMC9402626 | 2022-Aug-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.BMC Cancer | PMID 35999527PMC9400287 | 2022-Aug-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.JAMA | PMID 35997729PMC9399866 | 2022-Aug-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH).BMC Cancer | PMID 35999521PMC9400297 | 2022-Aug-23 | 0.70 | The study is a Phase III randomized oncology trial with planned OS and DFS endpoints, but it is a protocol without results. Furthermore, the intervention (perioperative corticosteroid flash dose) is a supportive care measure, not a standard systemic drug therapy for the cancer, and the primary endpoint is a safety/morbidity outcome. | 待处理 |
| Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.Nat Commun | PMID 35995785PMC9395368 | 2022-Aug-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.N Engl J Med | PMID 36070710PMC9945922 | 2022-Aug-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |